Impact of Asthma Treatments on Daily Activities
Study on Asthma Treatments on Daily Activities as Reported by Patients (STAR)
Study Overview
Status
Status
Study Type
Study Type
Enrollment
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Nita Ngo, MPH
- Phone Number: 888.631.9167
- Email: asthmastudy@ovation.org
Study Locations
-
-
California
-
San Francisco, California, United States, 94105
- Recruiting
- Ovation Research Group
-
Principal Investigator:
- Susan D Mathias, MPH
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have asthma and allergies
- Currently taking Xolair® or Advair®
- Started Xolair® treatment within the last 4 to 12 months OR have been taking Advair® for at least 12 months
- Between 18 and 55 years of age
- A non-smoker for at least 6 months
- Have internet access
Study Plan
How is the study designed?
Design Details
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Susan D Mathias, MPH, Ovation Research Group
Study record dates
Study Major Dates
Study Start
Study Start
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1467
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.